Chih-Heng Huang

Chih-Heng Huang

Auto-generated profile, based on publicly available information

Chih-Heng Huang

Institute of Preventive Medicine, National Defense Medical University , Taipei 114

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2020 in ACS Nano
Verified
Journal Article
Closed access
NPNikhil Pathak
Nikhil Pathak
YCYun Ti Chen
Yun Ti Chen
YHYen-Chao Hsu
Yen-Chao Hsu
NHNung-Yu Hsu
Nung-Yu Hsu
CKChih Jung Kuo
Chih Jung Kuo
JYJinn-Moon Yang
Jinn-Moon Yang

14 January 2026 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
ACAn-Yu Chen
An-Yu Chen
YCYen-Chen Chen
Yen-Chen Chen
Wen-Hui FangWen-Hui Fang
Wen-Hui Fang
LLLe-Tien Lin
Le-Tien Lin
YHYi-Jen Hung
Yi-Jen Hung
CHChih-Heng Huang
Chih-Heng Huang
Background: Understanding the extent of cross-protection conferred by the historic smallpox vaccination and the immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) after the 2022 global mpox outbreak is essential to inform current prevention strategies. In this study, we assessed the seropositivity and neutralizing capacities of the vaccinia virus (VACV)- and monkeypox virus (MPXV)-specific antibodies in 260 Taiwanese patients. Methods: We analyzed serum samples from 260 individuals in Taiwan, stratified by their birth year, before or after 1979, the year of smallpox vaccination cessation. ELISA and plaque reduction neutralization tests were conducted to assess VACV- and MPXV-specific antibody responses. Furthermore, we evaluated an additional cohort of MVA-BN vaccines (n = 9) before and after vaccination. Results: Over 80% of individuals born before 1979 retained VACV-reactive antibodies, with 84% of this seropositive subgroup exhibiting neutralizing activity. We detected cross-reactive MPXV antibodies in 69% of individuals who were VACV-seropositive; however, only 65% had MPXV-neutralizing capacity, with titers significantly lower than those against VACV. MVA-BN vaccination enhanced VACV and MPXV antibody levels; however, MPXV-neutralizing titers remained low, particularly in individuals without prior smallpox immunization. Conclusion: Historical smallpox vaccination induces long-lasting humoral immunity, and a correlation between VACV and MPXV antibody levels further suggests that it provides some degree of cross-protection against MPXV infection. MVA-BN boosted orthopoxvirus immunity; however, it may be limited in MPXV neutralization in vaccine-naïve populations. These findings offer useful insights for future mpox vaccination strategies and public health planning in regions with varying smallpox vaccination histories.